ALN-6400HMBeacon: A Phase 2 Study to Evaluate ALN-6400 in Adult and Adolescent Female Patients With VWD and HMB

Sponsor:

Alnylam Pharmaceuticals

Code:

NCT07575308

Conditions

Von Willebrand Disease (VWD)

Heavy Menstrual Bleeding (HMB)

Eligibility Criteria

Sex: Female

Age: 16 - 45

Healthy Volunteers: Not accepted

Interventions

ALN-6400

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-08-27. This information was provided to ClinicalTrials.gov by Alnylam Pharmaceuticals on 2026-08-12.